ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: NIH Alumni Assn. Formed; Jenney Named Kans. Vice Chancellor; Bloomfield To Move To RPMI

June 9, 1989

Chemo, Radiation Improves DFS In Head & Neck Cancer

May 28, 2004

Varmus Pools $13.4 M. To Fund Projects; NCI Gives $2.6 Mil.

December 9, 1994

Substance From Sea Squirts In Phase II For Breast Cancer

November 29, 2002

Large Phase III Trial Seeks Optimal Use Of Tykerb vs. Herceptin In Breast Cancer

February 29, 2008

CGAP Speeding Gene Discovery

April 30, 1999